



## **CURRICULUM VITAE**

**JOHN R. P. TESSER, MD, FACP, FACR**

### **BUSINESS ADDRESS**

AmeRuss Clinical Trials, LLC  
10599 N. Tatum Blvd. Suite F-150  
Paradise Valley, Arizona 85253  
Phone: (480) 443-8400  
Fax: (480) 443-7420

### **EDUCATION**

#### **UNDERGRADUATE**

1969 – 1973 Yale University, New Haven, Connecticut  
B.A. cum laude

#### **GRADUATE**

1973-1977 University of Rochester - School of Medicine & Dentistry  
Medical Degree, Rochester, New York

#### **POST GRADUATE**

1977-1978 Maricopa County General Hospital  
Phoenix, Arizona, Categorical Medicine Internship  
Maricopa County General Hospital, Phoenix, Arizona

1978-1980 Residency in Internal Medicine  
Bowman Gray School of Medicine  
Winston-Salem, North Carolina

1980-1982 Fellowship in Rheumatology and Associate in Internal Medicine

#### **BOARD CERTIFICATIONS**

1980 Diplomate of the American Board of Internal Medicine in the Specialty of  
Internal Medicine

1982 Diplomate of the American Board of Internal Medicine in the Subspecialty  
of Rheumatology

1998 International Society of Clinical Densitometry

2002 Recertification

**LICENSURE**

1978 Arizona 11285

**CURRENT PROFESSIONAL ACTIVITIES**

Practicing Rheumatologist

Arizona Arthritis & Rheumatology Associates, P.C.  
10599 N. Tatum Boulevard, Suite F-150  
Paradise Valley, AZ 85253

Arizona Arthritis & Rheumatology Associates, P.C.  
9305 West Thomas Road, Suite #505  
Phoenix, AZ 85037

Clinical Lecturer in Internal Medicine  
University of Arizona Health Sciences Center  
Tucson, Arizona  
1986 - Present

Adjunct Assistant Professor  
Division of Clinical Education  
Midwestern University, Arizona College of Osteopathic Medicine  
Phoenix, Arizona  
1998-Present

**PREVIOUS PROFESSIONAL ACTIVITIES**

Medical Director and Principal Investigator  
Radiant Research Phoenix  
Phoenix, Arizona 85015  
2003 – 2006

Director, Arizona Rheumatology Center  
Phoenix, Arizona 85015  
1992 - 2004

Chief Principal Investigator, Phoenix Center for Clinical Research  
(a Division of Protocare Sciences, Inc.)  
Phoenix, AZ 85015  
1998 – 2003

Medical Director, Phoenix Center for Clinical Research  
Phoenix, Arizona 85015  
1992 – 1998

Arthritis and Rheumatism  
Official Journal of the American College of Rheumatology  
Peer Reviewer  
1999

Associate Chairman, Department of Medicine  
 Maricopa Medical Center  
 Phoenix, Arizona  
 1990 - 1992

Acting Chairman, Department of Medicine  
 Maricopa Medical Center  
 Phoenix, Arizona  
 1989 - 1990

Chief of Rheumatology  
 Maricopa Medical Center  
 Phoenix, Arizona  
 1982 - 1992

Clinical Assistant Professor of Medicine  
 University of Arizona Health Sciences Center  
 Tucson, Arizona  
 1984 - 1986

#### **PROFESSIONAL MEMBERSHIPS/AFFILIATIONS**

Fellow, American College of Physicians  
 Fellow, American College of Rheumatology  
 American Society of Bone and Mineral Research  
 International Society for Clinical Densitometry

#### **MISCELLANEOUS PRESENTATIONS**

1. Sjogren's Syndrome. "New Concepts in Rheumatic Disease" (Conference) in Tempe, Arizona. October 23-24, 1982
2. Pulse Methylprednisolone Therapy in the Treatment of Rapidly Progressive Scleritis Wegener's Granulomatosis. Edwards D, Tesser JRP. Arizona Regional Meeting of the American College of Physicians, October 21, 1983, Tucson, Arizona
3. Neuropsychological Evaluation of SLE Cerebritis. Tesser JRP, Johnson PI, Cooper K, Gluck O, American Rheumatism Association, Western Regional Meeting, Tucson, Arizona. February 24, 1984
4. Treatment Modalities of Raynaud's Syndrome and Scleroderma. Therapeutic Advances in Rheumatic Diseases (Course) Good Samaritan Regional Medical Center, Phoenix, Arizona. April 28, 1984
5. ADFR Coherence Therapy. Them Ol' Bones II: Conference on Musculoskeletal Diseases in the Aged, Scottsdale, Arizona. March 7, 1985
6. Osteoporosis: New Treatment Method. Arizona Medical Association Meeting, Scottsdale, Arizona. April 25, 1985
7. Osteoporosis: Update in Clinical Medicine. Postgraduate Course-American College of Physicians, Scottsdale, Arizona November 5, 1986

8. Osteoporosis: Clinical Management System, Arizona Medical Association, 1987 Annual Meeting, Phoenix, Arizona. June 4, 1987
9. Systemic Lupus Erythematosus: Update on a Decade. Update in Clinical Medicine, Postgraduate Course-American College of Physicians, Scottsdale, Arizona. October 30, 1989
10. Adult Onset Still's Disease Complicated by the Hemophagocytic Syndrome. Arizona Rheumatology Association, Sedona, Arizona June, 1991
11. Gout: The Chemical, the Crystal, the Disease. Update in Clinical Medicine. Postgraduate Course-American College of Physicians, Scottsdale, Arizona. November 12, 1991
12. Results of a Multi-Dose Protocol 7002 Using an Immunomodulating, Non-Depleting Primatized Anti-CD4 Monoclonal Antibody in Rheumatoid Arthritis (RA) Kaine J, Solinger A, Yocum D, Lipani J, Klas P, Tesser JRP, Wiesenhutter C, O'Sullivan F, Shuman S, Rigby W. Arthritis Rheum. Presented at the 1995 Meeting of the American College of Rheumatology
13. RA: Aggressive Treatment and the Cutting Edge. Grand Rounds, St. Joseph's Hospital and Medical Center. May 1996
14. RA: Newer Treatment Methods. Presented at the Arizona Rheumatology Association Meeting, Sedona, Arizona June, 1996
15. Steroid Induced Osteoporosis. Presented at the Arizona Rheumatology Association Meeting, Sedona Arizona June, 1996
16. The Prevention and Treatment of Osteoporosis. Presented at the 20th Annual Midwinter Symposium, Maricopa Health Systems, March 7, 1997
17. Treatment of rheumatoid arthritis with a primatized anti-cd4 monoclonal antibody SB-210396 (IDEC-CE9.1) - results of an open label extension study in patients responding to induction therapy. Presented at American College of Rheumatology's 61st National Meeting, November 8, 1997
18. Redefining the role of NSAIDs in arthritis: toward an improved safety profile. Presented for Searle's Western Region CME Program. February 26, 1998 and March 21, 1998
19. Osteopenia in a Rheumatology Practice. Presented at the 5th Annual International Society for Clinical Densitometry Meeting in New Orleans. January 16, 1999
20. New Treatments for Rheumatoid Arthritis. Visiting Professor CME Presentation for Grand Rounds at Olympia Hospital, Olympia Fields, Illinois. February 19, 1999
21. The Science of Cox-2 Technology. Western Region CME Presentation at Casa Grande Regional Medical Center, Casa Grande, AZ. March 18, 1999
22. Cox II Inhibitors. CME Program Presented to the Medical Staff at Phoenix Baptist Hospital, Phoenix, AZ, April 6, 1999
23. The Science of Cox-2 Technology in the Treatment of Arthritis. Western Region CME Program Presented to The Arizona State Association of Physician Assistants, Sedona, AZ April 22, 1999
24. Update on the Diagnosis and Treatment of Rheumatoid Arthritis. CME Presentation to the Medical Staff at Yuma Regional Medical Center, Yuma, AZ, April 28, 1999
25. Inflammatory Myopathies. Good Samaritan Residency Program, May 2, 1999
26. Inflammatory Myopathies. St. Joseph's Residency Program, June 15, 1999

27. The Management of Arthritis. Hospital Orientation, Good Samaritan and VA Hospital Physicians, June 30th & July 1st, 1999
28. Bone up on the Facts: Osteoarthritis vs. Osteoporosis. Arthritis Foundation Lay Public Lecture, July 13, 1999
29. Rheumatoid Arthritis and Lupus: What's New and Most Current Treatments. WEBB MD, August 24, 1999
30. Cox II Inhibitors: Phoenix Art Museum, September 30th and October 20th, 1999.
31. Recent Developments in Osteoarthritis: Scottsdale Healthcare Grand Rounds, December 17, 1999
32. Radiographic Progression of Rheumatoid Arthritis in Clinical Trials using Remicade, Arava & Enbrel: Statewide Rheumatology Association Meeting, Sedona, AZ June 10, 2000
33. RA New Therapeutic Agents: Good Samaritan/St. Joe's Hospital Resident Lecture Series, June 7th and 15th, 2000
34. Rheumatoid Arthritis: Maricopa County Medical Center, Medical Resident Lecture, Phoenix, AZ, June 30, 2000
35. Rheumatoid Arthritis: Mesa General Hospital, Physician Round Table, Mesa, AZ, September 5th, 2000
36. Osteoporosis: Roundtable, Phoenix, AZ, October 4, 2000
37. Osteoporosis: Lay Public Lecture, Arthritis Foundation Wellness Expo, October 7, 2000
38. IL-1-ra: Grand Rounds, University of Arizona College of Medicine, Tucson, AZ, January 19, 2001
39. Gout and Hyperuricemia: Good Samaritan/St. Joe's Hospital Resident Lecture Series, April 4, and April 17, 2001
40. Inflammatory Arthritis Work Up: Spring 2001 Primary Care Conference, Sedona, AZ, April 27, 2001
41. IL-1 in Rheumatoid Arthritis: IRN First Annual Meeting, Las Vegas, NV, June 9, 2001
42. PEG STNF-R1 Improves Health-related Quality of Life in Patients with Rheumatoid Arthritis, Presented at the Annual Meeting of the European Congress of Rheumatology, Prague, Czech Republic, June 13-16, 2001
43. Grand Rounds:"Gout and Hyperuricemia" UNT Health Sciences Center, Dallas Fort Worth, TX, September 21, 2001
44. Grand Rounds: "Il-1RA" Maricopa County Medical Center, Phoenix, AZ, October 26, 2001
45. IL-1RA: Safety Data: IRN Meeting, Las Vegas, NV, January 19, 2002.
46. Poster Presentation:"The Safety of Kineret (Anakinra) in combination with other RA Therapies" European League Against Rheumatism, Annual European Congress of Rheumatology "EULAR 2002" Stockholm, Sweden June 12-15, 2002.
47. Poster Presentation: "A Safety Trial of Kineret (Anakinra): Recombinant Interleukin-1 receptor antagonist (IL-1RA), in a large, placebo controlled heterogeneous population of patients with rheumatoid arthritis" European League Against Rheumatism, Annual European Congress of Rheumatology "EULAR 2002" Stockholm, Sweden June 12-15, 2002.

48. Rheumatology Regional Consultancies Organizing Faculty: European League Against Rheumatism Annual European Congress of Rheumatology- EULAR 2003 Key Clinical Update, Lisbon, Portugal June 18-21, 2003.
49. REACH Regional West Summit Meeting: "Safety in Biologic Treatment of RA Patients", Santa Monica, CA, June 6-7, 2003.
50. European League Against Rheumatism 2003 Key Clinical Update: New York City, NY, July 19, 2003, and Chicago, IL, July 25, 2003.
51. Review of Immunology 2003: Phoenix Orthopedic Residency Program, Phoenix, AZ September 18, 2003.
52. Early and Aggressive Treatment of RA: Wyeth Consultants Meetings, Phoenix, AZ and Dallas, TX, December 8<sup>th</sup> & December 15<sup>th</sup>, 2003.
53. American College of Rheumatology 2003 Key Clinical Update: San Francisco, CA, November 22<sup>nd</sup>, 2003.
54. Maintaining Motion: Advances in Anti-TNF Therapy for the Treatment of Rheumatic Diseases, San Antonio, TX, December 17<sup>th</sup>, 2003.
55. Grand Rounds: Osteoporosis Update in Diagnosis and Management, Banner Good Samaritan Hospital, Phoenix, AZ, May 2005.
56. Grand Rounds: Osteoporosis Update in Diagnosis and Management, St. Joseph's Hospital and Medical Center, Phoenix, AZ June 2005.

## PUBLICATIONS

1. Weinblatt ME, **Tesser J**, Gilliam, III J: The Liver in Rheumatic Diseases. *Semin Arthritis Rheum* 11(no 4):399-405, 1982.
2. **Tesser J**, Pisko E, Hartz J, and Weinblatt M: Chronic Liver Disease and Still's Disease. *Arthritis Rheum* 25:579-82, 1982.
3. **Tesser J**, Rothberger H, Agudelo C: The Clinical Significance of Anti-Cytoplasmic Antibodies found on Fluorescent Antinuclear Antibody Testing. *J Rheum* 10:227-34, 1983.
4. Wall B, Agudelo C, **Tesser J**, et al: An Autopsy Study of the Prevalence of Monosodium Urate and Calcium Pyrophosphate Dihydrate Crystal Deposition in First Metatarsophalangeal Joints. *Arthritis Rheum* 26:1522-24, 1983.
5. Gluck O, **Tesser J**, Howard P: Lupus: New Pathophysiologic Insights and Lupus: Improvements in Management. *Drug Therapy* 15:62-84, 1985.
6. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, McKendry R, **Tesser J**, Baker P, Wells G: Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis. *N Engl J Med* 333:137-41, 1995.
7. Silverman S, Gluck O, Silver D, **Tesser J**, Wallace D, Newumann K, Metzger A, Morris R: The Prevalence of Autoantibodies in Symptomatic and Asymptomatic Patients with Breast Implants and Patients with Fibromyalgia. *Curr Top Microbiol Immunol, Immunology of Silicones* 210:317-26, 1996 .
8. Tenenbaum SA, Rice JC, Espinoza LR, Cuellar ML, Plymale DR, Sander DM, Williamson LL, Haislip SM, Gluck OS, **Tesser JRP**, Nogy L, Stribny KM, Bevan JA, Garry RF. Use of antipolymer antibody assay in recipients of silicone breast implants. *Lancet* 349:449-54, 1997.
9. Gluck OS, **Tesser JRP**. Bone Mineral Density and Inflammatory Arthritis: Overview of the recent medical literature. *Scan:IV*(no 1):1-3, 1997.
10. Stein, M, Pincus T, Yocum D, Tugwell T, Wells G, Gluck O, Kraag G, Torley H, **Tesser J**, McKendry R, Brooks RH for the Methotrexate-Cyclosporine

- Combination Study Group: Combination treatment of severe rheumatoid arthritis with cyclosporine and methotrexate for forty-eight weeks. *Arthritis Rheum* 40:1843-51,1997.
11. **Tesser J**, Gluck O. Pro: Conservative vs. Aggressive therapy for steroid induced osteoporosis. *The Journal of Osteoporosis: Index & Reviews* 1(no 1):4-8:1998.
  12. **Tesser J**, Gluck O, Maricic M, Yocum D. Rheumatoid arthritis: aggressive treatment and the cutting edge. *Journal of the Irish Colleges of Physicians and Surgeons* 25(no 1):29-32,1998.
  13. Yocum DE, Solinger AM, **Tesser J**, Gluck O, Cornett M, O'sullivan F, Nordensson K, Dallaire B, Shen C, Lipani J. Clinical and Immunologic Effects of a primatized anti-CD4 monoclonal antibody in active rheumatoid arthritis: results of a phase I, single dose, dose escalating trial. *J Rheumatol* 25(no 7):1257-62, 1998.
  14. Maricic M, **Tesser J**, Chen Z, Lund P, Gluck O: How Often Does Lateral Spine DXA Detect Low Bone Mass in Patients with Both Normal PA Spine and Hip? *Journal of Clinical Densitometry* 1(no 3):251-57, 1998.
  15. Chen Z, Maricic M, Lund P, **Tesser J**, Gluck O: How the New Hologic Hip Normal Reference Values Affect the Densitometric Diagnosis of Osteoporosis. *Osteoporosis Int* 8:423-27, 1998.
  16. Wilson R, Gluck O, **Tesser J**, Rice J, Meyer A, Bridges A: Antipolymer Antibody Reactivity in a Subset of Patients with Fibromyalgia Correlates with Severity. *J Rheumatol* 26(no 2):402-07, 1999.
  17. Bathon Joan M, Martin Richard W, Fleischmann Ray M, **Tesser John R**, Schiff Michael H, Keystone Edward c, et al: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med* 343(22):1586-1593, 2000.
  18. Moreland, L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms R, **Tesser J**, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human Interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. *Arthritis Rheum* 3:247-252, 2001.
  19. Mason U, Aldrich J, Breedveld F, Davis CB, Elliott M, Jackson M, Jorgensen C, Keystone E, Levy R, **Tesser J**, Totoritis M, Truneh A, Weisman M, Wiesenhutter C, Yocum D, Zhu J: CD4 coating, but not CD4 depletion, is a predictor of efficacy with primatized monoclonal anti-CD4 treatment of active rheumatoid arthritis. *J Rheumatol* 29(2):220-9, 2002.
  20. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, **Tesser JR**, Schiff MH, Keystone EC, Wasko MC, Moreland LW, Weaver AL, Markenson J, Cannon GW, Spencer-Green G, Finck BK. Etanercept versus methotrexate in patients with early rheumatoid arthritis. *Arthritis Rheum* 46(6):1443-50, 2002.
  21. Fleischmann R, Schechtman J, Bennett R, Handel M, Burmester G, **Tesser J**, Modafferi D, Poulakos J, Sun G. Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis. *Arthritis Rheum* 48(4):927-934, 2003.
  22. **Tesser J**, Fleischmann R, Dore R, et. Al. Concomitant medication use in a large international multicenter placebo controlled trial of Anakinra, a recombinant IL-1 receptor antagonist, in patients with RA. *J Rheumatol* 31(4):649-654, 2004.

23. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schectman J, Hartman S, Liu T, Solinger AM. The safety of Anakinra in high-risk patients with active rheumatoid arthritis. *Arthritis Rheum* 50(6):1752-1760;2004.
24. Bathon JM, Fleischmann RM, van de Heijde DM, **Tesser JR**. Safety and efficacy of entanercept treatment in elderly subjects with rheumatoid arthritis. *J Rheumatol* 33(2):234-243, 2005.

## ABSTRACTS

1. Agudelo C, Rothberger H, and **Tesser J**: Diagnostic Significance of Anti-Cytoplasmic Antibodies (ACA) as Compared to Antinuclear Antibodies (ANA) in Human Serum. Proceedings of the Fifteenth International Congress of Rheumatology - Revue Du Rheumatisme, Et. Des Maladies Osteo-Articulaires, Abstract #448, ILAR Special number for June, 1981.
2. **Tesser J**, Rothberger H, and Agudelo C: The Clinical Significance of Anti-Cytoplasmic Antibodies (ACA) Found on Routine Antinuclear Antibody Testing. *Arthritis Rheum* 25:S108, 1982.
3. Wall B, Agudelo C, **Tesser J**, Mountz J, and Holt D: Incidence of Monosodium Urate (MSU) and Calcium Pyrophosphate Dihydrate (CPPD) Crystalline Deposits in 1st Metatarsophalangeal (MTP) Joints: An Autopsy Study. *Arthritis Rheum* 25:S34, 1982.
4. **Tesser J**, Johnson P, Cooper K, and Gluck O: Neuropsychological Evaluation of SLE Cerebritis. Presented at the Western Regional Meeting of the American Rheumatism Ass. Feb. 1984.
5. Howard P, **Tesser J**, Gluck O: Thiazide Diuretics are Protective Against Bone Loss in Postmenopausal Women with Rheumatic Disease. Presented at the Western Regional Meeting of the American Rheumatism Ass. Nov. 1984.
6. Stein C, Pincus T, Brooks R, Tugwell P, Wells G, Yocum D, **Tesser J**, Cornett M, Lipani J: Combination Therapy with Cyclosporine and Methotrexate: Results of a 24 week Extension Study Subsequent to a 24 week Double-blind Study. *Arthritis Rheum* 37(suppl 9):S252, 1994.
7. Solinger A, Yocum D, **Tesser J**, Gluck O, O'Sullivan F, Henkel C, Cornett M, Lipani J: Clinical Activity in an Early Phase I Trial of Primatized IDEC-CE9.1 - An Anti-CD4 Monoclonal Antibody in RA. *Arthritis Rheum* 37(suppl 9):S337, 1994.
8. Gluck O, **Tesser J**, Tenenbaum S, Garry R, Espinoza L: Silicone related Disorders - Clinical and serological Description. *Lupus* 4( suppl 2): March 1995.
9. Tenenbaum S, Rice D, Plymale D, Sander R, Wilson R, Garry S, Gluck O, **Tesser J**, Weinrib L, Stribny K, Bevan J, Cuellar M, Espinoza L: Diagnostic and Clinical Criteria Distinguishing Silicone Disorders from Classical Rheumatic Diseases. *Arthritis Rheum* 38(suppl 9):S325, 1995.
10. Kaine J, Solinger A, Yocum D, Lipani J, Klas P, **Tesser JRP**, Wiesenhutter C, O'Sullivan F, Shuman S, Rigby W: Results of a Multi-Dose Protocol 7002 Using an Immunomodulating, Non-Depleting Primatized Anti-CD4 Monoclonal Antibody in Rheumatoid Arthritis (RA). *Arthritis Rheum* 38(suppl 9):S185, 1995.
11. Birbara C A, Fiddes R A, Khairi R, Bockow B, Siegel E, **Tesser J**, Birnbaum A, Pritchard C, Karr R, Rajkumar R S: Double-Blind, Vehicle-Controlled Study of

- Topical Civamide in Knee Osteoarthritis. *Arthritis Rheum* 39(suppl 6):R14, 1996.
12. Gluck O S, **Tesser JRP**, Tenenbaum S A, Rice J, Sander D M, Plymale D R, Garry R F, Wilson R B. Development of a Laboratory Marker for Fibromyalgia. *Arthritis Rheum* 39(suppl 9):S90, 1996.
  13. Maricic M, **Tesser J**, Chen Z, Lund P, Gluck O, Comparison of AP and Lateral Spine DEXA in Osteoporosis. Present at the International Society for Clinical Densitometry Third Annual Meeting, January 1997.
  14. Saag K, Emkey R, Gruber B, **Tesser J**, Lane N, Yanover M, Dubois C, Freedholm D, Carofano W, Daifotis A. Alendronate for the management of glucocorticoid-induced osteoporosis: results of the multi-center U.S. study. *Arthritis Rheum* 40(suppl 9):S136, 1997.
  15. Evans J, Yocum D, Maricic M, Gluck O, **Tesser J**, Chen Z, Baylink D, Fletcher M. Results of an open label, dose-ranging, safety and pharmacokinetic trial of the humanized tumor necrosis factor antibody (HTA), bay 103356, in patients with active rheumatoid arthritis (RA) *Arthritis Rheum* 40(suppl 9):S224, 1997.
  16. **Tesser J**, Wiesenhutter C, Levy R, Schiff M, Lipani J, Solinger A, MacDonald B, Elliott M, Singh K. Treatment of rheumatoid arthritis with a primatized anti-cd4 monoclonal antibody SB-210396 (IDEC-CE9.1) - results of an open label extension study in patients responding to induction therapy. *Arthritis Rheum* 40(suppl 9):S224, 1997.
  17. Hawkins F, Epstein S, Hamdy N, **Tesser J**, Malice M, Daifotis AG, Espinosa D. Do Disease and Concomitant Medications Influence the Effect of Alendronate on Spine BMD in Patients Receiving Glucocorticoids? *Arthritis Rheum* 41(suppl 9):S302, 1998.
  18. Kavanaugh A, Paulus H, Olsen N, Weisman M., Matteson E, Furst D, Van Vollenhoven R, Genovese M, St. Clair EW, **Tesser J**, Winkelhake JMocci S, Jacobs C, Shulman M. Allele- and antigen-specific treatment of rheumatoid arthritis: a double blind, placebo controlled phase I trial. *Arthritis Rheum* 42(suppl 9): S78, 1999.
  19. Moreland L, Chase W, Fife R, Hillson J, Greco T, Korn J, **Tesser J**, Weisman M, King K, Lyons D, Gugliotti R. Phase I/II study evaluating the safety and potential efficacy of recombinant human interleukin-11(rhIL-11) in patients with refractory rheumatoid arthritis. *Arthritis Rheum* 42(suppl 9): S171, 1999.
  20. Genovese M, Keystone EC, **Tesser JRP**, Finck BK, Spencer-Green . High dose oral methotrexate (MTX) in early RA is needed for maximum efficacy. *Arthritis Rheum* 43(suppl 9): 1228, 2000.
  21. **Tesser J**, Schiff M, Davis M, Woolley M. PEG STNF-RI improves health-related quality of life in patients with rheumatoid arthritis. *Ann Rheum Dis* 60(suppl I):OP0044, 2001.
  22. Gluck O, **Tesser J**, Lawless G, Wade S, Goldberg G, Batra D, Kadlubek P. Incidence of clinically relevant infections associated with rheumatoid arthritis. *Ann Rheum Dis* 60(suppl I):FR10032, 2001.
  23. Fleischman R, **Tesser J**, Schechtman J, Modafferi D, Poulakos J, Bennett R, Burmester G, Handel M, Sun G . Safety Trial of Anakinra: Recombinant Interleukin-1 Receptor Antagonist (IL-1RA), in a Large Placebo Controlled Heterogeneous population of Patients with Rheumatoid Arthritis. *Arthritis Rheum* 44(suppl 9):S84, 2001.

24. Burch F, **Tesser J**, Bell L, Kivitz A. Baseline C5b-9 Level Correlates with CRP and ACR 20 Response to the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis. *Arthritis Rheum* 44(suppl 9):S214, 2001.
25. Kivitz A, Burch F, Birbara C, Rollins S, **Tesser J**. Pharmacokinetics (PK) and Pharmacodynamics (PD) of the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis. *Arthritis Rheum* 44(suppl 9):S214, 2001.
26. **Tesser J**, Kivitz A, Fleischman R, Mojcik C, Bombara M, Burch F. Safety and Efficacy of the Humanized Anti-C5 Antibody h5G1.1 in Patients with Rheumatoid Arthritis. *Arthritis Rheum* 44(suppl 9):S274, 2001.
27. Moreland, L, Gugliotti R, King K, Chase W, Weisman M, Greco T, Fife R, Korn J, Simms **R**, **Tesser J**, Hillson J, Caldwell J, Schnitzer T, Lyons D, Schwertschlag U. Results of a phase-I/II randomized, masked, placebo-controlled trial of recombinant human Interleukin-11 (rhIL-11) in the treatment of subjects with active rheumatoid arthritis. *Arthritis Rheum* 44(suppl 9):247-252, 2001.
28. **Tesser J**, Schectman J, Dore R, et. al. The Safety of Kineret (Anakinra) in combination with other RA Therapies *Ann Rheum Dis* 61(suppl 1):175, 2002.
29. Fleischman R, **Tesser J**, Schechtman J, et. al. A Safety Trial of Kineret (Anakinra): Recombinant Interleukin-1 receptor antagonist (IL-1RA) in a large, placebo controlled heterogeneous population of patients with rheumatoid arthritis *Ann Rheum Dis* 61(suppl 1):184, 2002.
30. **Tesser J**, Gluck O, Lawless G, et. al. Healthcare resources utilization attributed to infections in patients with rheumatoid arthritis: *Ann Rheum Dis* 61(suppl 1):184, 2002.
31. Fleischmann R, **Tesser J**, Sun G, Safety of anakinra (Interleukin-1 Receptor Antagonist) in patients receiving standard treatments for rheumatoid arthritis: a large phase III study. *Arthritis Rheum* 46(suppl 9):S574, 2002.
32. Fleischmann R, **Tesser J**, Schechtman J, Sun G. Safety of anakinra (Interleukin-1 receptor antagonist) in rheumatoid arthritis (RA) subjects with potential high risk for infection. *Arthritis Rheum* 46(suppl 9):S343, 2002.
33. Bergstrom L, Yocum D, **Tesser J**, Miller M, Lisse J, Gluck O. Coccidiomycosis (Valley Fever) occurring during infliximab therapy. *Arthritis Rheum* 46(suppl 9):S169, 2002.
34. Bergstrom L, Yocum D, Villanueva I, Ampel N, Gluck O, **Tesser J**, Lisse J. Coccidioidomycosis in patients treated with TNF-alpha antagonists is a primary infection, not reactivation. *Arthritis Rheum* 48(suppl 9):S626, 2003.
35. Fleischmann, R, **Tesser J**, Bekker P, Bell D, Zhou L, Modafferi D. Long-term safety of anakinra (interleukin-1 receptor antagonist) in patients receiving standard treatments for rheumatoid arthritis: A 26-month update from a large phase 3 study. *Arthritis Rheum* 48(suppl 9) S330, 2004.
36. Bathon JM, Fleischmann RM, van de Heijde DM, **Tesser JR**. Safety and efficacy of entanercept treatment in elderly subjects with rheumatoid arthritis. *Arthritis Rheum* 52(suppl 9) S542, 2005.

## MONOGRAPHS

1. **Tesser J**. "Clinical Trials of IL-1Based Therapy". Clinical monograph series: The Role of IL-1 in the Pathogenesis of Rheumatoid Arthritis, AMGEN, February 2001, pp. 25-32.

2. O'Dell J., **Tesser J.** Clinical monograph series: "The Evolution of the Treatment Paradigm of Rheumatoid Arthritis: Cytokine-Mediated Disease and Current Therapies" *AMGEN, October 2003, pp. 25-3.*

### **CLINICAL RESEARCH EXPERIENCE**

1. An Open-Label, Chronic Safety Study Of XXXX In Sjogren's Syndrome Patients With Xerostomia And Keratoconjunctivitis Sicca
2. A Double Blind, Randomized, Placebo-Controlled Study Of XXXX In Sjogren's Syndrome Patients With Xerostomia And Keratoconjunctivitis Sicca
3. A Multi-Center, Double Blind, Placebo-Controlled, Parallel Group, Clinical Study To Evaluate The Safety Of Topical XXXX Gel In The Treatment Of Pain Associated With Osteoarthritis Of The Knee
4. A Clinical Evaluation Of The Effects Of XXXX And XXXX Used Sequentially On XXXX Induced Endometrial Hyperplasia
5. An Open-Label, Multi-Center, Long-Term Extension Study To Assess The Safety Of Re-Treatment With XXXX In Patients With Rheumatoid Arthritis
6. Rheumatoid Arthritis Genetic Epidemiology Study
7. A Double Blind, Placebo Controlled Comparative Study Of The Efficacy And Upper Gastrointestinal Safety Of XXXX, XXXX, XXXX In Treating The Signs And Symptoms Of Osteoarthritis
8. A Multi-Center, Double-Blind, Parallel Group Study Comparing The Incidence Of Gastroduodenal Ulcer Associated With XXXX With That Of XXXX Taken For 12 Weeks In Patients With Osteoarthritis Or Rheumatoid Arthritis
9. A Six-Week Open-Label, Multi-Center Safety Study Of XXXX In Patients With Rheumatoid Arthritis
10. A Randomized Six-Week Double Blind, Placebo And Positive-Controlled Parallel-Group Multi-Center Dose Ranging Study Of XXXX In Patients With Rheumatoid Arthritis
11. A Double Blind, Randomized, Controlled Study To Compare XXXX + XXXX Vs. Placebo + XXXX In Patients With Severe Active Rheumatoid Arthritis
12. A Double Blind, Multi-Center Study Testing XXXX Immediate Release To XXXX Sustained Release In Patients With Chronic Pain
13. Placebo Controlled Comparison Of The Efficacy And Safety Of XXXX Extended Release With XXXX In Patients With Active Rheumatoid Arthritis Followed By A Long-Term Open-Label Extension

14. A Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study On The Efficacy And Safety Of XXXX During 3 Years Treatment In Patients With Postmenopausal Osteoporosis And Vertebral Fractures Using Continuous Oral XXXX Daily And An Intermittent Oral XXXX Every 2<sup>nd</sup> Day For 24 Days Every 3 Months Dosing Regimen
15. One-Year Study Of XXXX Dosing In Patients With Osteoarthritis Or Rheumatoid Arthritis
16. *A Double-Blind, Placebo Controlled, Randomized Comparison Study Of The Efficacy And Safety Of Two Doses Of XXXX Bid And XXXX Bid In Treating The Signs And Symptoms Of Osteoarthritis*
17. *A Multi-Center, Double-Blind, Placebo Controlled, Randomized Comparison Study Of The Efficacy And Upper Gastrointestinal Safety Of XXXX, XXXX And XXXX Bid And XXXX Bid In Treating The Signs And Symptoms Of Rheumatoid Arthritis*
18. *Clinical Protocol To Evaluate The Long-Term Safety Of XXXX In Treating The Signs And Symptoms Of Osteoarthritis And Rheumatoid Arthritis*
19. A Double Blind, Placebo Controlled Comparison Study Of The Efficacy And Safety Of Two Doses Of XXXX Bid And XXXX Bid In Treating The Signs And Symptoms Of Rheumatoid Arthritis
20. A Multi-Center, Double-Blind, Placebo Controlled, Randomized Comparison Study Of The Efficacy And Upper Gastrointestinal Safety Of XXXX And XXXX
21. A Double Blind, Randomized, Placebo-Controlled Study To Compare The Safety And Efficacy Of XXXX With Placebo In Patients With Active Rheumatoid Arthritis
22. A Long-Term, Open-Labeled XXXX Trial Of A Single Daily Dose Of XXXX In Post-Menopausal Women
23. A Multi-Center, Randomized, Double-Blind, Parallel Group, Placebo And Active Controlled Study Of The Safety And Efficacy Of XXXX Applied Every Three Days For Sixty Days Vs. XXXX Tablets Vs. Placebo In Patients With Chronic Pain Due To Osteoarthritis
24. A Long-Term, Open-Label, Clinical Use Safety Study Of XXXX (Transdermal Delivery System) Applied Every 72 Hours For The Management Of Ongoing Pain Syndromes
25. A Double Blind, Placebo-Controlled, Randomized Comparison Study Of The Efficacy And Safety Of XXXX, XXXX Or XXXX Bid And XXXX Bid In Treating The Signs And Syndromes Of Osteoarthritis Of The Hip

26. A Four-Week Double Blind, Placebo Controlled Comparison Of The Safety And Efficacy Of Orally Administered XXXX And XXXX In Patients With Active Osteoarthritis Of The Knee.
27. A Four-Week, Placebo Controlled, Comparison Of The Efficacy And Safety Of Orally Administered XXXX And XXXX In Patients With Degenerative Joint Disease Of The Knee Followed By A Twelve Week Double-Blind Comparison Of XXXX And XXXX
28. A Double Blind, Placebo-Controlled Study To Assess The Safety And Pharmacokinetics Of XXXX When Administered Alone, Or In Combination With XXXX, In Patients With Active Rheumatoid Arthritis
29. Effects Of XXXX In The Treatment Of Post-Menopausal Women With Osteoporosis
30. A Double Blind, Placebo Controlled Study To Evaluate Safety And Tolerability And Preliminarily Assess Clinical Efficacy Of XXXX In Patients With Osteoarthritis Of The Knee
31. A 12-Month, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Extension Study To Evaluate The Continued Safety And Efficacy Of Two Doses Of Oral XXXX For The Prevention And Treatment Of Glucocorticoid-Induced Bone Loss
32. A Double Blind, Placebo Controlled Study To Assess Safety And Efficacy And Preliminarily Evaluate Clinical Efficacy Of XXXX In Patients With Rheumatoid Arthritis
33. Evaluation Of The Relative Potency And Safety Of XXXX With XXXX, Compared To XXXX With XXXX In Chronic Pain Or Benign Origin
34. An Open-Label Study Of Individual Patients With Osteoarthritis Or Rheumatoid Arthritis
35. An Evaluation Of The Efficacy And Safety And Nsaid Sparing Effect Of XXXX Compared To Placebo In Subjects With Osteoarthritis Pain
36. A Double Blind, Comparison Of Three Intravenous Doses Of XXXX Administered Twice Weekly For Four Weeks, Compared To Placebo In The Treatment Of Patients With Stable, Active Rheumatoid Arthritis
37. A Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study Comparing The Efficacy And Safety Of Oral Tablets Of XXXX Acetate As Well As XXXX Alone Against Placebo In The Prevention Of Osteoporosis In Postmenopausal Women
38. A Phase II, 6-Month, Double Blind, Placebo Controlled, Parallel-Group Study Of Oral XXXX In Hip Fracture Patients

39. A Phase III, Randomized, Placebo-Controlled Study To Compare The Activity And Safety Of XXXX To XXXX Or Placebo In Subjects With Active Rheumatoid Arthritis
40. A Placebo-Controlled Comparison Of The Safety And Efficacy Of Two Doses Of XXXX With XXXX In Patients With Osteoarthritis Of The Knee
41. A Placebo-Controlled Comparison Of The Safety And Efficacy Of Two Doses Of XXXX Extended Release With XXXX In Patients With Osteoarthritis Of The Knee
42. A Phase II Double Blind, Randomized, Controlled Comparison Of Oral XXXX With Placebo In Adult Patients With Active Rheumatoid Arthritis Following Abrupt Withdrawal Of XXXX Therapy
43. An Open Label Dose Ranging, Safety And Pharmacokinetic Study Of The XXXX In Subjects With Active Rheumatoid Arthritis
44. A Randomized, Modified, Double Blind, Placebo-Controlled, Parallel Group Trial To Evaluate The Efficacy And Dose-Response Of A New XXXX In The Prevention Of Post-Menopausal Bone Loss
45. A 12-Month, Randomized, Double Blind, Placebo-Controlled, Multi-Center Study To Evaluate The Safety And Efficacy Of Two Doses Of Oral XXXX For The Prevention And Treatment Of Glucocorticoid-Induced Bone Loss
46. A Sequential Trial Of XXXX Anti-Rheumatic Therapy
47. Multicenter, Double-Blind, Placebo-Controlled, Randomized Study On The Efficacy And Safety Of XXXX During 3 Years Of Treatment In Patients With Postmenopausal Osteoporosis And Vertebral Fractures Using A Continuous Oral XXXX And An Intermittent Oral XXXX (Every 2<sup>nd</sup> Day For 24 Days Every 3 Months) Dosing Regimen
48. Multicenter Double-Blind Randomized Phase III Study Comparing XXXX To XXXX In Treatment Of Patients With Early Active Rheumatoid Arthritis
49. A Randomized, Double Blind, Placebo-Controlled Trial Of The Effect Of XXXX In The Prevention Of Bone Loss In Early Postmenopausal Women
50. Double-Blind Randomized, Stratified, Parallel-Group Study To Assess The Incidence Of Pub's During Chronic Treatment With XXXX Or XXXX In Patients With Rheumatoid Arthritis: U.S. Cohort
51. A Randomized, Double Blind, Placebo-Controlled Trial Of The Effect Of XXXX In The Prevention Of Osteoporosis In Postmenopausal Women With Low Bone Density

52. A Multi-Center, Open-Label Study Evaluating The Safety And Tolerability Of XXXX Controlled-Release Tablets In Patients With Chronic Pain
53. A Long Term Open Label Extension Trial Of A Single Daily Dose Of XXXX In Postmenopausal Women
54. Open-Label Extension Treatment With XXXX For Participating Patients In XXXX Clinical Trials
55. Extension Trial Of The Comparison Of The Activity And Safety Of XXXX And XXXX In Subjects With Active Rheumatoid Arthritis
56. A Fourth Double-Blind, Active Comparator-Controlled Extension Of A Placebo-Controlled, Double-Blind Study To Assess Safety And Further Define The Clinically Effective Dose Range Of XXXX In Patients With Osteoarthritis Of The Knee Or Hip
57. Two-Part, Double-Blind, Randomized, Multicenter, Parallel-Group, 52 Week Study To Assess The Safety And Tolerability, And To Further Define The Clinically Effective Dose Range Of XXXX In Patients With Rheumatoid Arthritis
58. Clinical Protocol To Evaluate The Long-Term Safety Of XXXX In Treating The Signs And Symptoms Of Osteoarthritis And Rheumatoid Arthritis
59. A Long-Term, Open Label, Clinical Use Safety Study Of XXXX Tds (Transdermal Delivery System) XXXX Applied Every 7 Days For The Management Of Ongoing Pain Syndromes
60. A Double Blind, Double-Dummy, Randomized, Parallel Group, Multicenter Comparison Of The Efficacy And Safety Of XXXX And XXXX In Patients With Active Rheumatoid Arthritis (6 Month Efficacy Study) Who Are Candidates For Immunosuppressive Therapy Of Rheumatoid Arthritis
61. Clinical/Endoscopic Effects Of XXXX And XXXX In Elderly (> 65 Years Of Age) Patients With Moderate To Severe Osteoarthritis Of The Knees And/Or Hips
62. Multicenter, Randomized, Placebo-Controlled Extension Study To XXXX: Safety And Disease Activity Of Multiple Doses Of Subcutaneous XXXX In Patients With Active Rheumatoid Arthritis
63. Multicenter, Randomized, Placebo-Controlled Extension Study To XXXX: Safety And Disease Activity Of Multiple Doses Of Subcutaneous XXXX In Patients With Active Rheumatoid Arthritis
64. A Double Blind, Phase IIb, Multiple Doses, Adjuvant-Controlled Study Of XXXX And XXXX Therapeutic Vaccines In Patient With Active Rheumatoid Arthritis

65. A Multi Center, Double Blind, Placebo-Controlled, Repeat Dose-Ranging Phase I / II Study Of XXXX In Patients With Moderate To Severe Rheumatoid Arthritis
66. A 24-Week Study To Evaluate The Safety And Efficacy Of XXXX Therapy In The Presence Of Background XXXX In Patients With Active Rheumatoid Arthritis
67. A Multicenter, Active Comparator And Partially Placebo-Controlled, 15-Month Study Of The Effects Of XXXX Vs. XXXX On Biochemical Indices Of Bone Turnover And Bone Density In Patients With Osteoarthritis
68. A 24-Week Study To Evaluate The Safety And Efficacy Of XXXX Therapy In The Presence Of Background XXXX In Patients With Active Rheumatoid Arthritis
69. A Randomized, Double Blind, Placebo-Controlled Trial To Examine Cd+ T Cell Depletion In Patients With Active Rheumatoid Arthritis Receiving XXXX
70. A Dose Ranging, 24-Week Trial Of XXXX In Patients With Primary Knee Osteoarthritis With Or Without Hand Osteoarthritis (Followed By A 30 Month Extension)
71. Safety And Efficacy Of XXXX For Preventing Bone Loss In Normal, Early Postmenopausal Women
72. A Triple-Blind, Randomized, Parallel Efficacy Study Of XXXX In Patients With Mild To Moderate Essential Hypertension
73. An Open-Label, Long-Term Safety And Activity Study Of XXXX Therapeutic Vaccine In Patients With Active Rheumatoid Arthritis
74. An Open Label Extension Study To Assess The Safety And Efficacy Of Long-Term Treatment With XXXX In Patients With Rheumatoid Arthritis And To Assess The Pharmacoeconomic Impact Of Treatment With XXXX Compared To A Usual Care Population
75. A Phase I, Double Blind, Randomized, Placebo-Controlled, Dose Escalation Study To Evaluate The Safety, Tolerability And Biological Activity Of A 2-Week Induction Course And 1 Maintenance Cycle Of XXXX In Subjects With Rheumatoid Arthritis
76. Phase II, Randomized, Double Blind, Placebo-Controlled, Multi-Center Regimen- And Dose-Finding, Safety And Histopathological Study Of XXXX (XXXX) In Severe Osteoarthritis Of The Knee

77. A Multicenter, Double Blind, Randomized, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of A Continuous Subcutaneous Infusion Of XXXX In Patients With Rheumatoid Arthritis
78. A Double-Blind, Randomized, Placebo-Controlled Study To Compare The Safety And Efficacy Of XXXX With Placebo In Patients With Active Rheumatoid Arthritis, Not Currently Receiving XXXX Therapy
79. An Open-Label, Multicenter, Long-Term Study To Assess The Safety Of Retreatment With XXXX In Patients With Rheumatoid Arthritis
80. An Open-Label, Multicenter, Single Dose, Dose Rising Clinical Trial To Evaluate The Safety And Efficacy Of Nine Dose Levels Of XXXX By Intra-Articular Administration In Patients With Active Rheumatoid Arthritis
81. *A Double Blind, Randomized, Placebo Controlled Study To Evaluate The Safety And Efficacy Of XXXX As Adjunct To Background Anti-Rheumatoid Therapy, In Preventing Structural Joint Damage In Rheumatoid Arthritis*
82. Double-Blind Randomized, Stratified, Parallel-Group Study To Assess The Incidence Of Pub's During Chronic Treatment With XXXX Or XXXX In Patients With Rheumatoid Arthritis: U.S. Cohort
83. A Phase II Randomized, Double Blind, Placebo-Controlled Study Of The Effect Of XXXX On Rheumatoid Arthritis Patients Receiving XXXX
84. A One-Year Randomized, Placebo- And Active-Comparator-Controlled, Parallel-Group, Double-Blind, 2-Part Study To Assess The Safety And Efficacy Of XXXX Vs. XXXX In Patients With Osteoarthritis
85. A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Dose-Finding Study To Evaluate The Safety And Efficacy Of Weekly Administration Of XXXX In Patients With Rheumatoid Arthritis
86. Multicenter, Randomized, Placebo-Controlled Efficacy And Safety Study Of XXXX Plus Stable Dosing Of XXXX In Subjects With Active Rheumatoid Arthritis
87. A Double-Blind Extension Study To Provide Treatment With XXXX To Subjects Completing Clinical Trials A Or B In The Treatment Of Rheumatoid Arthritis
88. An Active-Comparator - And Placebo-Controlled, Parallel-Group, Double-Blind, 52-Week Study To Assess The Safety And Efficacy Of XXXX In Rheumatoid Arthritis Patients
89. A Multicenter, Randomized, Blinded, Placebo Controlled Study To Describe Long-Term Safety Of Daily Subcutaneous Injections Of XXXX In Patients With Rheumatoid Arthritis

90. A Four-Week Comparative Study Evaluating XXXX Extended Release And XXXX In The Treatment Of Osteoarthritis Of The Knee
91. Evaluation Of XXXX As Initial Therapy And The Addition Of XXXX As Subsequent Therapy To Subjects With Active Rheumatoid Arthritis
92. A Placebo Controlled, Parallel Group, 4-Week, Trial Conducted Under Double Blind Conditions To Assess The Efficacy And Safety Of XXXX In Patients With Chronic Low Back Pain
93. An Active-Comparator - And Placebo-Controlled, Parallel-Group, Double-Blind, 52-Week Study To Assess The Safety And Efficacy Of XXXX In Rheumatoid Arthritis Patients
94. A Multicenter, Double-Blind, Randomized, Parallel-Group, Active- And Placebo-Controlled Study With In-House Blinding To Compare Mean Gastric Erosion Scores After 10-Weeks Of Treatment With XXXX Once Weekly Vs. Placebo
95. A Randomized, Parallel-Group, Double-Blind Study To Evaluate The Efficacy Of Xxxmg, Xxxmg, Xxxmg, And Xxxmg Of XXXX In Patients With Osteoarthritis Of The Knee
96. *A Multicenter, Double Blind, Randomized Study To Evaluate The Efficacy And Safety Of Combination Treatment With XXXX And XXXX In Subjects With Rheumatoid Arthritis Receiving XXXX*
97. A Twelve-Week, Randomized, Double Blind, Placebo-Controlled, Dose-Ranging Study Of XXXX In Patients With Rheumatoid Arthritis
98. A Randomized, Double Blind, Trial Of XXXX In Combination With XXXX Compared With XXXX Alone For The Treatment Of Patients With Early Rheumatoid Arthritis
99. Clinical Protocol For A Double Blind, Placebo And Active-Controlled Comparison Of The Analgesic Activity Of XXXX, XXXX, And Placebo In Post-Bunionectomy Surgical Patients
100. A Comparative Efficacy And Safety Study Of XXXX Delayed-Release Capsules Vs. Placebo For The Healing Of XXXX-Associated Gastric Ulcers When Daily XXXX Use Is Discontinued
101. A Randomized, Double Blind, Placebo-Controlled, Dose Finding Study Of XXXX (Topical Gel Formulation Of XXXX And XXXX) For The Treatment Of Male Erectile Dysfunction In An At-Home Setting
102. An Open-Label Continuation Trial Of X% XXXX (Topical Gel Formulation Of XXXX And XXXX In Male Erectile Dysfunction Patients Who Previously

## Participated In XXXX Study

103. A Randomized, Multi-Center, Double Blind, Placebo Controlled Study Of The Iontophoretic Administration Of XXXX In The Treatment Of Patients With Acute Epicondylitis
104. Double Blind, Randomized, Dose-Titration, Parallel-Group Comparison Of The Efficacy And Safety Of XXXX And Placebo In The Treatment Of Osteoarthritis Of The Knee
105. Open Label Assessment Of The Safety And Effectiveness Of XXXX In The Treatment Of Chronic Non-Malignant Pain
106. Double Blind, Placebo-Controlled, Parallel-Group Comparison Of The Efficacy And Safety Of XXXX Placebo In The Treatment Of Chronic Low Back Pain
107. A 13 Week, International, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group Assessing The Safety And Efficacy Of XXXX In Patients With Knee Primary Osteoarthritis, Using XXXX As A Comparator
108. A 26-Week, Randomized, Double Blind, Active-Controlled, Multi-Center, Parallel Group Study To Investigate The Gastrointestinal Safety Of XXXX Compared To XXXX In Patients With Osteoarthritis Of The Knee
109. A Multicenter, Randomized, Double-Blind, Placebo-Controlled, 12 Month Study To Evaluate The Efficacy And Safety Of Oral XXXX Once Weekly For The Prevention And Treatment Of Glucocorticoid-Induced Bone Loss
110. A Phase II, Randomized, Double-Blind, Placebo-Controlled 51-Day Study To Evaluate The Safety And Biological Effect Measured By Type II Collagen Neo-Epitopes (Tiine) In Urine Of Subjects With Osteoarthritis (Oa) Caused By Distinct 42-Day Multiple Dose Oral Regimens Of XXXX
111. XXXX Vs. Placebo In The Treatment Of Fibromyalgia Patient With Or Without Major Depressive Disorder
112. Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison Of The Efficacy And Safety Of Controlled Release XXXX And Placebo In The Treatment Of Osteoarthritis Of The Knee And/Or Hip
113. *A Randomized, Double Blind, Multicenter, Vehicle-Controlled Study To Compare The Safety Of An Oral Buffered Solution Of XXXX Once Weekly Vs. An Oral Buffered Solution Without XXXX For The Treatment Of Osteoporosis In Men And Postmenopausal Women*

114. *A Multicenter, Open-Label, Multidose, 52-Week Study Designed To Assess The Safety Of XXXX In The Treatment Of Moderate To Severe Non-Malignant Chronic Pain*
115. *A Phase II, Randomized, Double Blinded, Placebo-Controlled, Parallel-Group, Multicenter, Clinical Trial To Evaluate The Safety And Efficacy Of Three Doses Of XXXX Vs. Placebo And XXXX In Patients With Osteoarthritis Of The Knee*
116. *A Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Safety And Efficacy Of Three Doses Of XXXX Conjugated Estrogens (Modified Release Tablets) Compared With Placebo In Hysterectomized Postmenopausal Women For The Prevention Of Osteoporosis*
117. *A Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Efficacy And Systemic Absorption Of A XXXX Topical Patch In The Treatment Of Distal Subungual Onychomycosis Of The Great Toenail*
118. *A Multicenter, Open-Label, Multidose, 52-Week Study Designed To Assess The Safety Of XXXX In The Treatment Of Moderate To Severe Non-Malignant Chronic Pain*
119. *XXXX Comparison In Postmenopausal Women With Osteoporosis*
120. *A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study With A Withdrawal Phase To Investigate The Safety And Efficacy Of XXXX Or XXXX In Female Patients With Constipation-Predominate Irritable Bowel Syndrome*
121. *A Double-Blind, Randomized Trial Of Intra-Articular Injection Of XXXX Into The Glenohumeral Articular Space For The Treatment Of Chronic Painful Shoulder*
122. *A 52-Week, Open-Label, Multicenter Study Of The Long-Term Safety And Efficacy Of XXXX In Patients With Constipation-Predominant And Alternating-Type Irritable Bowel Syndrome*
123. *Clinical Protocol For A Double-Blind, Randomized Three Arm, Two Period, Crossover Study To Compare XXXX, XXXX, And Placebo In Patients With Osteoarthritis Of The Hip Or Knee*
124. *An International, Multicenter, Stratified, Randomized, Double-Blind, Double-Dummy, Parallel-Group, 52-Week Gastrointestinal Clinical Safety Study To Demonstrate That XXXX Reduces The Risk To Develop Complicated Ulcers As Compared To XXXX In Osteoarthritis Patients*

125. *A 4-Week, Randomized, Double-Blind, Placebo- And Positive-Controlled, Parallel-Group, Multicenter Study Of XXXX In Patients With Osteoarthritis Pain Of The Hip Or Knee*
126. *A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase-III Trial Of The Efficacy And Safety Of XXXX In Male Patients With Erectile Dysfunction*
127. *A Randomized, Double-Blind, Placebo-Controlled Study Evaluating XXXX Extended Release (1950 Mg/Day And 3900 Mg/Day) In The Treatment Of Osteoarthritis Of The Hip And Knee*
128. *Clinical Protocol For A Randomized, Double-Blind, Active And Placebo Controlled, Parallel Group, Single And Multiple Dose Assessment Of The Analgesic Efficacy Of XXXX Formulation B Following Bunionectomy*
129. *Double-Blind, Randomized, Dose-Ranging, Parallel-Group Comparison Of The Efficacy And Safety Of Extended Release XXXX, XXXX, And Placebo In The Treatment Of Osteoarthritis Of The Knee*
130. *A Randomised, Multicenter, Double Blind, Double Dummy, Placebo Controlled, Parallel Group, Multiple-Dose, Phase II B Study To Assess The Efficacy And Safety Of XXXX In Comparison To XXXX In Patients With Chronic Hip Or Knee-Joint Osteoarthritis*
131. *An Open-Label, Parallel Design, Twelve Month Phase III Trial Of The Safety And Efficacy Of XXXX In Male Patients With Erectile Dysfunction*
132. *A Randomized, Placebo-Controlled Clinical Trial To Evaluate The Effects Of XXXX Consumption On Blood Pressure In Overweight Men And Women With Mild Hypertension*
133. *A 12-Week, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group Study To Investigate The Efficacy And Safety Of XXXX In Patients With Osteoarthritis (Oa) Of The Knee*
134. *A Randomized, Double-Blind, Multicenter Study To Evaluate The Tolerability And Effectiveness Of XXXX Vs. XXXX In Patients With Osteoarthritis*
135. *A Phase III Randomized, Multicenter Study Comparing The Safety And Efficacy Of Oral XXXX Vs. XXXX In Subjects With Gout*
136. *A Multi-Center, Double-Blind, Randomized, Parallel-Group Trial To Compare The Efficacy And Safety Of Three Doses Of XXXX And Placebo In Patients With Rheumatoid Arthritis*

137. A Randomized, Double-Blind, Placebo-Controlled Study Of The Safety, Efficacy And Systemic Absorption Of A XXXX Topical Patch In The Treatment Of Distal Subungual Onychomycosis Of The Great Toenail
138. *A Multicenter International Observational Study Of The Long-Term Safety Of XXXX In Crohn's Disease*
139. *A Dose Range-Finding, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study To Assess The Safety, Tolerability, And Efficacy Of XXXX In Obese Subjects*
140. *Clinical Protocol For A Multiple Dose Randomized, Double-Blind, Placebo Controlled Study Of The Analgesic Efficacy And Safety Of XXXX Compared To Placebo In Patients For Treatment Of Post-Surgical Pain From Bunionectomy Surgery*
141. *A 13-Week, Multicenter, International, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study Of 2 Doses Of XXXX In Patients With Rheumatoid Arthritis Using XXXX As A Comparator*
142. A Randomized, Double-Blind, Active-Comparator-Controlled, Parallel-Group Study To Evaluate The Safety Of XXXX In Patients With Osteoarthritis Or Rheumatoid Arthritis
143. A Phase III, 12-Month, Double Blind, Randomized, Parallel Group, Placebo-Controlled, Efficacy And Safety Study Of Two Dose Levels Of XXXX In Overweight And Obese Subjects With A 6-Month Open-Label Extension Phase
144. Safety Evaluation Of XXXX With XXXX In Opioid Tolerant Patients
145. *A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Use Study To Evaluate The Safety And Tolerability Of XXXX Administered Intravenously To Subjects With Active Rheumatoid Arthritis With Or Without Medical Co-Morbidities Receiving Disease Modifying Anti-Rheumatic Drugs And/Or Biologics Approved For Rheumatoid Arthritis*
146. *Phase III Contraception Study Of XXXX Subcutaneous Injection In Women Of Childbearing Potential In The Americas (Including A Bone Mineral Density [Bmd] Substudy Comparing The Effects Of XXXX-Sc And XXXX-Im.) Also Including A Return Of Ovulation Substudy*
147. *A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Determine The Efficacy And Safety Of XXXX In Subjects With Moderate To Severe Chronic Osteoarthritic Pain Of The Hip Or Knee*

148. A Four-Arm Study Comparing The Analgesic Efficacy And Safety Of XXXX Once A Day And XXXX Vs. Placebo For The Treatment Of Pain Due To Osteoarthritis Of The Knee
149. A 12-Week Randomized, Placebo- And Active Comparator-Controlled, Parallel-Group, Double Blind, Study To Assess The Efficacy Of XXXX Vs. XXXX In Patients With Osteoarthritis
150. *A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study To Evaluate And Compare The Effects Of Once Weekly XXXX And XXXX On Bone Mineral Density In Postmenopausal Women With Osteoporosis*
151. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of XXXX In The Treatment Of Rapid Ejaculation
152. A Randomized, Double Blind, Multicenter, Study To Evaluate The Tolerability And Effectiveness Of XXXX Vs. XXXX In Patients With Rheumatoid Arthritis
153. A Randomized, Double-Blind, Placebo-Controlled, Single Attack, Parallel-Group Evaluation Of The Efficacy Of XXXX Tablets Vs. Placebo In The Treatment Of Subjects Who Affirm Tension, Tension-Type Or Stress Headaches And Who Meet The International Headache Society Criteria For Migraine
154. A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study To Evaluate The Safety And Efficacy Of XXXX And XXXX In Patients With Osteoarthritis Of The Knee
155. A 13-Week, Multi-Center, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial Of 2 Different Dose Regimens Of XXXX In Patients With Primary Knee Osteoarthritis, Using XXXX As A Comparator
156. *An Open-Label Effectiveness And Safety Study Of XXXX Extended Release In Opioid-Naïve Patients With Chronic Pain*
157. *A Phase III, Randomized, Multicenter, XXXX- And Placebo-Controlled Study Assessing The Safety And Efficacy Of Oral XXXX In Subjects With Gout*
158. *A Randomized, Double-Blind, Phase 3 Study To Compare The Efficacy And Safety Of XXXX And XXXX Vs. XXXX In Risk Reduction Of Non-Steroidal Anti-Inflammatory-Associated Ulcers In Osteoarthritis Subjects Taking Low Dose XXXX*
159. An Open Label Study Of The Long Term Safety Of XXXX In The Treatment Of Rapid Ejaculation

160. *Fracture Incidence Reduction And Safety Of XXXX Compared To Placebo And Raloxifene In Osteoporotic Postmenopausal Women*
161. A 13 Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial Of 2 Different Dose Regimens Of XXXX In Patients With Primary Knee Osteoarthritis, Using XXXX
162. A Multicenter, Double-Blind, Active-And Placebo-Controlled Efficacy And Safety Study Of XXXX And XXXX In Patients With Low Back Pain
163. *A Multicenter, Double-Blind, Randomized, Placebo- And XXXX Controlled Study To Assess Safety And Efficacy Of XXXX In The Prevention Of Postmenopausal Osteoporosis*
164. *A Randomized, Placebo-Controlled, Double-Blind, Parallel Design Phase 3 Bridging Trial Of The Efficacy And Safety Of XXXX In Male Patients With Erectile Dysfunction*
165. An Open-Label, Parallel Design, Long-Term Phase 3 Trial Of The Safety And Efficacy Of XXXX Male Patients With Erectile Dysfunction
166. A Multinational, Multicenter, Randomized, Double-Blind, Parallel Group, Active Controlled, Comparative Trial, To Assess The Endometrial Histological Profile Following Treatment With XXXX Versus Conjugated Estrogen (Ce) Plus Medroxyprogesterone Acetate (Mpa)} In Postmenopausal Women
167. A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial To Determine The Efficacy And Safety Of The XXXX In Subjects With Moderate To Severe Chronic Osteoarthritic Pain Of The Hip Or Knee
168. A Randomized, Multiple-Dose, Double-Blind, Placebo-Controlled, Parallel-Group Study Comparing The Safety And Efficacy Of XXXX And XXXX In Subjects With Non-Malignant Pain
169. A Randomized, Double-Blind, Multicenter, Active-Control Study Evaluating The Efficacy And Safety Of XXXX In Subjects With Moderate To Severe Osteoarthritis Pain
170. A One Year, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Dose-Finding, Safety, Tolerability And Efficacy Study Of XXXX In Postmemopausal Women With Osteopenia/Osteoporosis Supplemented With Calcium And Vitamin D
171. A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Use Study To Evaluate The Safety And Tolerability Of XXXX Administered Intravenously Subjects With Active Ra With Or Without Medical Co-Morbidities Receiving Disease Modifying Anti-Rheumatch Drugs And/Or Biologics Approved For Ra

172. A Phase III, Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of XXXX Vs. XXXX In Subjects With Active Rheumatoid Arthritis On Background Dmards Who Have Failed Anti-Tnf Therapy
173. A Phase III, Multi-Center, Randomized, Double Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of XXXX In Combination Therapy With XXXX Alone In Subjects With Active Rheumatoid Arthritis And Inadequate Response To XXXX
174. A Double-Blind, Placebo Controlled, Parallel Group, Dose Ranging Comparison Of The Efficacy And Safety Of XXXX And Placebo In The Treatment Of Osteoarthritis Of The Knee And/Or Hip
175. A Phase 3, Multicenter, Open-Label Study To Evaluate The Safety And Efficacy Of XXXX And XXXX In A Continuous Daily Regimen For Oral Contraception
176. A Randomized, Double-Blind, Multicenter Study To Evaluate The Tolerability And Effectiveness Of XXXX Versus XXXX In Patients With Rheumatoid Arthritis
177. A Randomized, Double-Blind, Phase 3 Study To Compare The Efficacy And Safety Of XXXX And XXXX Versus XXXX In Risk Reduction Of Non-Steroidal Anti-Inflammatory-Associated Ulcers In Osteoarthritis Subjects Taking Low Dose Aspirin
178. A Phase III Pivotal, Multicenter, Double-Blind, Randomized, Placebo-Controlled, Mono-Therapy Study Of XXXX For Treatment Of Fibromyalgia
179. XXXX Comparison In Postmenopausal Women With Osteoporosis
180. A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study To Evaluate And Compare The Effects Of Once Weekly XXXX On Bone Mineral Density In Postmenopausal Women With Osteoporosis (Fact)
181. Efficacy And Safety Of XXXX Administered During 8 Weeks In Patients With Sleep Disorders In Fibromyalgia: Multicenter, Randomized, Double-Blind, Placebo-Controlled Study.
182. A Double-Blind, Parallel, Placebo-Controlled, Randomized Study To Evaluate The Efficacy And Safety Of 3 Different Oral Dose Levels (To Be Confirmed 1, 2, And 4 Mg) Of XXXX In Subjects With Active Rheumatoid Arthritis On Concomitant XXXX Therapy
183. A Randomized, Double-Blind, Active-Comparator, Parallel-Group Study To Evaluate The Safety Of XXXX In Patients With Osteoarthritis Or Rheumatoid Arthritis

184. Extended Follow-Up Of Patients In XXXX (Study Drug) Trials
185. XXXX Safety Under Long Term Study....Results
186. A Phase III Open-Label Study To Assess The Long-Term Safety Of XXXX Subjects With Gout
187. A Multicenter, Randomized, Blinded Placebo Controlled Study To Describe Long-Term Safety Of Daily Subcutaneous Injections Of XXXX In Patients With Rheumatoid Arthritis
188. A Randomized, Parallel-Group, Double-Blind Study To Evaluate The Safety And Efficacy Of XXXX In Patients With Osteoarthritis Of The Knee
189. A 16-Week, Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose, Parallel Group, Multicenter Study With A Withdrawl Phase To Investigate The Safety And Efficacy Of XXXX In Female Patients With Constipation-Predominant Irritable Bowel Syndrome
190. A Multicenter, Double-Blind, Randomized, Placebo-Controlled Comparison Of The Effects On Sexual Functioning Of Extended-Release XXXX And XXXX In Outpatients With Moderate To Severe Major Depression Over Eight-Week Treatment Period.
191. A Phase III Randomized, Multicenter Study Comparing The Safety And Efficacy Of XXXX Versus XXXX In Subjects With Gout
192. Randomized, Double-Blind, Placebo-Controlled, Study Of The Analgesic Efficacy Of XXXX In Patients With Acute Joint Flare Pain Of The Knee Or Hip
193. A Randomized, Double-Blind, Multicenter Study To Evaluate The Tolerability And Effectiveness Of XXXX Vs XXXX In Patients With Osteoarthritis
194. An Open-Label Effectiveness And Safety Study Of XXXX In Opioid-Naïve Patients With Chronic Pain
195. A 12 Week, Randomized, Placebo- And Active Comparator-Controlled, Parallel Group, Double-Blind Study To Assess The Safety And Efficacy Of XXXX In Patients With Osteoarthritis
196. A Phase III, Randomized, Multicenter, Allopurinol And Placebo-Controlled Study Assessing The Safety And Efficacy Of XXXX In Subjects With Gout
197. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study Of The Efficacy And Safety Of XXXX In The Treatment Of Rapid Ejaculation
198. A 13 Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Trial Of 2 Different Dose Regimens Of XXXX In

Patients With Primary Knee Osteoarthritis, Using XXXX As A Comparator

199. Open Label Safety Evaluation Of XXXX In Opioid Tolerant Patients
200. A Four-Arm Study Comparing The Analgesic Efficacy And Safety Of XXXX Versus Placebo For The Treatment Of Pain Due To Osteoarthritis Of The Knee
201. A Double-Blind, Randomized Trial Of Intra-Articular Injection Of XXXX Into The Glenohumeral Articular Space For The Treatment Of Chronic Painful Shoulder With Limitation Of Motion Due To Glenohumeral Joint Osteoarthritis, Rotator Cuff Tear (Partial Or Complete) And/Or Primary Or Secondary Adhesive Capsulitis - (XXXX Use In Painful Shoulder - Hups)
202. Open Label Extension Treatment With XXXX For Participating Patients In XXXX Clinical Trials
203. Open-Label Extension Treatment With XXXX For Participating Patients In XXXX
204. A Randomized, Double-Blind, Trial Of XXXX In Combination With Methoxetrate Compared With Methoxetrate Alone For Treatment Of Patients With Early Rheumatoid Arthritis
205. An International, Multicenter, Stratified, Randomized, Double-Blind, Double-Dummy, Parallel Group, 52 Week Gastrointestinal Clinical Safety Study To Demonstrate That XXXX Reduces The Risk To Develop Complicated Ulcers As Compared To XXXX In Osteoarthritis Patients
206. A 13-Week, Multicenter, International, Randomized, Double-Blind, Placebo Controlled, Parallel-Group Study Of XXXX In Patients With Rheumatoid Arthritis Using Naproxen 500 Mg B.I.D. As Comparator
207. A Randomized, Double-Blind, Parallel, Multicenter, Placebo-Controlled, Two Year Study To Determine The Efficacy And Safety Of Orally Administered 5 And 15 Mg/Day, And 50 Mg/Week XXXX In Patients With Medial Compartment Knee Osteoarthritis In North America
208. A 52-Week, International, Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Clinical Trial To Compare Retention On Treatment, Safety, Tolerability And Efficacy Of XXXX, XXXX And XXXX In Patients With Primary Osteoarthritis Of Hip, Knee, Hand Or Spine
209. A Multi-Center, Double-Blind, Placebo-Controlled, Randomized Study Of XXXX, XXXX. And XXXX in the Treatment of Chronic Low Back Pain
210. A Placebo-Controlled, Double-Blind, Randomized, Parallel Study of the Withdrawal Effects of Chronic Daily and As Needed Dosing with XXXX in the Treatment of Premature Ejaculation

211. A 13-week, multicenter, randomized, double-blind, double-dummy, placebo-controlled, parallel group trial of XXXX in patients with primary hip osteoarthritis using XXXX as a positive control
212. An Open-Label Titration Followed By A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Tolerability, And Safety Of XXXX in Opioid-Naïve Patients With Chronic Low Back Pain
213. An Open-Label Titration Followed By A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Efficacy, Tolerability, And Safety Of XXXX in Opioid-Experienced Patients With Chronic Low Back Pain
214. A Randomized, placebo-controlled, blinded, multicenter Phase I/II study of the safety of escalating doses of XXXX in Subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant XXXX
215. A Comparison Of Prandial Insulin Lispro Mixtures Therapy To Glargine Basal-Bolus Therapy With Insulin Lispro On The Overall Glycemic Control Of Patients With Type 2 Diabetes Previously Treated With Oral Agents Combined With Insulin Glargine
216. A Phase 3, Double-Blind, Placebo-Controlled, Randomized, Parallel Group, Multicenter Study Of Efficacy, Safety And Tolerability Of Fixed Combination XXXX Administered Orally, Once Daily For 6 Months, Compared To XXXX Alone Or Placebo, In Subjects With Mixed Dyslipidemia Frederickson Types IIa And IIb
217. A Multicenter, Randomized, Placebo-Controlled, Phase III, Efficacy And Safety Study Of XXXX In Patients With Moderate To Severe Chronic Pain Due To Osteoarthritis Of The Hip Or Knee
218. A 2-Week Dosing, Randomized, Double-Blind, Placebo-And Positive-Controlled, Parallel-Group, Multicenter Study of XXXX in Subjects With Osteoarthritis Pain Of The Knee
219. A Study To Evaluate The Efficacy Of XXXX In The Treatment Of Osteoarthritis Of The Knee
220. A Randomized, Double-Blind, Placebo-Controlled, Multi-Dose Phase 2 Study To Determine The Efficacy, Safety, And Tolerability Of XXXX In The Treatment Of Postmenopausal Women With Low Bone Mineral Density
221. A Multicenter, Open-Label Extension Study To Assess The Long-Term Safety And Efficacy Of An Oral Calcimimetic Agent XXXX In Primary Hyperparathyroidism

222. A Double-Blind, Randomized Parallel Group Study To Evaluate The Safety, Tolerability And Efficacy Of XXXX Alone Or Co-Administered With XXXX In Subjects With Primary Dyslipidemia
223. A Randomized, Double-Blind, Placebo-Controlled Study To Assess The Subjective Response To Treatment With XXXX In Adult Subjects With Chronic Insomnia By Utilizing An Interactive Voice Response System (IVRS) For Collecting Diary Data
224. A Randomized, Placebo-Controlled, Parallel-Groups Study To Evaluate The Effects Of 1-Year Administration Of XXXX With Or Without Calcium And Vitamin D Supplements On Bone Mineral Density, Bone Biomarkers And Calcium Metabolism In Postmenopausal Women With Osteopenia
225. A Phase 3, Randomized, Multicenter, Double-Blind Study Comparing the Analgesic Efficacy of Extended Release XXXX/XXXX to Placebo in Subjects with Osteoarthritis
226. A Multicenter, Open-label continuation study in Moderate to Severe Chronic Plaque Psoriasis Subjects who completed a preceding psoriasis clinical study with {XXXX}
227. A Phase III, multicenter, open-label, extension study to evaluate the long-term safety of {XXXX} in women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS).
228. A Phase III, multicenter, randomized, double-blind, placebo-controlled, parallel group study of {XXXX} in women with Constipation-Predominant Irritable Bowel Syndrome (c-IBS).
229. A randomized, double-blind, placebo-controlled, parallel group, multi-center study comparing {XXXX} to {XXXX} and both active treatments to a vehicle control in the treatment of Tinea Versicolor.
230. An open-label study to assess the rate of failure of an {XXXX} in subjects with Rheumatoid Arthritis.
231. A 12-week, dose-ranging, double-blind, randomized, placebo-controlled, parallel-group study to assess the safety and efficacy of { } in obese patients.
232. A Phase II, Placebo-Controlled, Double-Blind, Dose-Ranging (35mg/day or 70 mg/day), Randomized, Multi-Center Study of XXXX in Older Hypogonadal Males Ages 55-80: Effect on Body Composition, Libido, and Physical and Sexual Functioning
233. Collection of {blood samples} from human subjects diagnosed with Multiple Sclerosis.

234. A Phase III, multicenter, randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of { XXXX } in the treatment of subjects with moderate to severe plaque-type Psoriasis.
235. A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of an Extended Cycle, Low Dose, Combination Oral Contraceptive Regimen, { XXXX } Which Utilizes XXXX During the Seven Day Interval Between Each 84-Day Cycle of Combination Therapy For the Prevention of Pregnancy in Women.
236. Efficacy and Safety of { XXXX } for Treating Heartburn in Frequent Sufferers
237. A Randomized, placebo-controlled, blinded, multicenter Phase I/II study of the safety of escalating doses of { XXXX } in Subjects with moderate to severe rheumatoid arthritis receiving stable doses of concomitant { XXXX }
238. A randomized, double-blind, multi-center, placebo-controlled, cross-over study to determine the consistency of response for { XXXX (XXXX) } administered during the mild pain phase for the acute treatment of multiple migraine attacks
239. Safety and Tolerability of the {Japanese Encephalitis Vaccine XXXX}. Double-blind, randomized, placebo controlled phase III study
240. Long Term Immunogenicity of The { XXXX }An Uncontrolled Phase 3 Follow Up Study
241. Direct Assessment of {Non-Vertebral Fractures} in Community Experience (XXXX)
242. Randomized, double-blind trial of { XXXX } tablets compared to placebo in patients with acute, painful musculoskeletal spasm of the lower back.
243. A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of XXXX Versus XXXX in Patients with Mixed Hyperlipidemia
244. A 4-Week, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety and Efficacy of { XXXX } in Patients With Osteoarthritis of the Knee or Hip.
245. A Phase III study of the analgesic efficacy and safety of { XXXX }: A parallel, randomized, double-blind, {13-week placebo-and Naproxen-controlled}, multicenter study of { XXXX } in patients with Osteoarthritis of the knee.
246. A Randomized, Double-Blind, Placebo- and Positive-Controlled Parallel-Group, Multicenter Study of {XXXX } Administered for 4 Weeks to Subjects with Osteoarthritic Pain of the Knee

247. A six-month, double-blind, placebo controlled, durability of effect study of { XXXX } for pain associated with Fibromyalgia.
248. Clinical {Specimen} Collection Study
249. A Randomized, Double-Blind, Placebo-Controlled, Single Dose, 12-Week, Proof-of-Concept, Efficacy and Safety of { XXXX } in Subjects With Osteoarthritis of the Knee
250. A randomized, double-blind, double-dummy, parallel group study of the safety and efficacy of { XXXX } vs { XXXX }, in patients with active Rheumatoid Arthritis.
251. { XXXX } with Chronic Low Back Pain Patients with or without Lower Extremity Pain -- A Randomized, Controlled, Parallel Groups Study
252. Efficacy and safety study of oral administration of XXXX for the Relief of Abdominal Pain or discomfort in patients with Irritable Bowel Syndrome (IBS). A randomized, placebo-controlled, parallel group, Dose-ranging (Phase IIB) trial.
253. Efficacy and safety of intra-articular multiple doses of XXXX including XXXX as calibrator in a randomized, double-blind, parallel-group, placebo-controlled 13-week multi-centre study in patients with symptomatic knee osteoarthritis
254. A Double-Blind, Multi-Center, Randomized, Parallel-Group, 16 Week Study of { XXXX } with or without a Low Calorie Diet Lead-in in Obese Males and Females
255. A randomized, double-blind, placebo-controlled, parallel group study to assess the effect of the {XXXX } on time to doubling of { XXXX }, end stage renal disease or death in patients with Type 2 Diabetes Mellitus and Diabetic Nephropathy.
256. A Phase III Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of { XXXX }in the Treatment of Vasomotor Symptoms in Postmenopausal Women
257. A Double-Blind, Randomized, Placebo- And Active-Controlled Efficacy and Safety Study of { XXXX} for Prevention of Endometrial Hyperplasia and Prevention of Osteoporosis in Postmenopausal Women
258. A Study to Evaluate the Efficacy of { XXXX } in the Treatment of Osteoarthritis of the Knee
259. A randomized, double-blind, placebo-controlled, parallel group, does finding study to investigate the safety, tolerability and efficacy of { XXXX } in post menopausal female subjects with low bone mineral density.

260. A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Extension Study to Investigate the Safety, Tolerability and Efficacy of XXXX in Post-Menopausal Women with Low Bone Mineral

Updated 7/20/07